LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
press release announcing its results of operations for its fiscal
quarter ended March 31, 2017. A copy of the press release is
furnished herewith as Exhibit 99.1.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release issued by Luminex Corporation dated May
1, 2017. |
About LUMINEX CORPORATION (NASDAQ:LMNX)
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease. LUMINEX CORPORATION (NASDAQ:LMNX) Recent Trading Information
LUMINEX CORPORATION (NASDAQ:LMNX) closed its last trading session up +0.10 at 18.93 with 169,833 shares trading hands.
